Soltamox Liquid
NDC Package 51862-682-01
Package Information
Soltamox (tamoxifen citrate) liquids is tamoxifen is used to treat breast cancer. This formulation utilizes a liquid delivery system. Marketed by Mayne Pharma, this product is identified by NDC 51862-682 and is authorized under FDA application NDA021807.
Identification & Billing
- RxCUI: 389230 - tamoxifen citrate 10 MG in 5 mL Oral Solution
- RxCUI: 389230 - tamoxifen 2 MG/ML Oral Solution
- RxCUI: 389230 - tamoxifen 10 MG (as tamoxifen citrate 15.2 MG) per 5 ML Oral Solution
- RxCUI: 389230 - tamoxifen 10 MG per 5 ML Oral Solution
- RxCUI: 644304 - SOLTAMOX 10 MG in 5 mL Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51862 - Mayne Pharma
- 51862-682 - Soltamox
- 51862-682-01 - 1 CONTAINER in 1 CARTON / 150 mL in 1 CONTAINER
- 51862-682 - Soltamox
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51862-682). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51862-682-01 identifies a specific commercial package of 1 container in 1 carton / 150 ml in 1 container of Soltamox, a human prescription drug labeled by Mayne Pharma. This liquid is formulated for oral use and contains tamoxifen citrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mayne Pharma on June 18, 2021. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.
How is this Mayne Pharma product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51862068201. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.